Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | S100A4 | P26447 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538993 | 1.00 | PTPRC (0.47) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL7408583 | 0.86 | CA2 (0.44) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL31449980 | 0.86 | CA2 (0.44) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL19552612 | 0.84 | CA2 (0.55) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL31444137 | 0.82 | PTPRC (0.47) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL23668294 | 0.80 | ALDH1A1 (0.52) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL29403247 | 0.80 | ALDH1A1 (0.60) | ALDH1A1CYP3A4PDE7APDE2APDE5A | |
| SCHEMBL31294301 | 0.80 | ALDH1A1 (0.52) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL15976059 | 0.80 | TDP1 (0.53) | PTPRCS100A4ALDH1A1CYP3A4PDE7A | |
| SCHEMBL452351 | 0.80 | ALDH1A1 (0.60) | ALDH1A1CYP3A4PDE7APDE2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117603097-B | Method for rapidly preparing 2-bromo-5-nitrobenzenesulfonyl chloride | 安徽泽升科技股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117603097-A | Method for rapidly preparing 2-bromo-5-nitrobenzenesulfonyl chloride | 安徽泽升科技股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-12582660-B2 | Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250136591-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-114514023-B | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3790541-B1 | N-(3-(AZEPAN-1-YLSULFONYI)-PHENYL)-2-((2-((3-PHENYL)AMINO)-2-OXOETHYL)(METHYL)AMINO)-ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RAS ONCOPROTEIN INHIBITORS FOR THE TREATMENT OF CANCER | UNIV LOUISVILLE RES FOUND INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | CYTEIR THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-0384276-B1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0384276-A1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-29 | — | — | EP | disclosed |
| US-4008208-A | Compositions having inhibited ability to promote platelet aggregation or fibrin clot formation | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3975371-A | Aromatic azo sulfonylnitrene compounds | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3954583-A | Photochemical process | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582660-B2 | Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof | KRAS, NRAS, HRAS | PTPRC 3064/4885S100A4 3278/4885ALDH1A1 1982/4885 |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | PTPRC 3044/4885S100A4 2468/4885ALDH1A1 4466/4885 |
| US-20250136591-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PTPRC 3688/4885S100A4 2289/4885ALDH1A1 4493/4885 |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | RAD51, MRE11, RAD52 | PTPRC 3044/4885S100A4 2468/4885ALDH1A1 4466/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PTPRC 3688/4885S100A4 2289/4885ALDH1A1 4493/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | PTPRC 1097/4885S100A4 332/4885ALDH1A1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.